- Home
- NG vs TSHA Comparison
NG vs TSHA Comparison
Compare NG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | TSHA |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NG | TSHA |
|---|---|---|
| Price | $9.98 | $5.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $10.17 | ★ $10.56 |
| AVG Volume (30 Days) | 2.5M | ★ 3.4M |
| Earning Date | 01-22-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.26 | $1.05 |
| 52 Week High | $10.90 | $6.02 |
Technical Indicators
Market Signals| Indicator | NG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 49.30 |
| Support Level | $8.92 | $5.58 |
| Resistance Level | $10.10 | $6.02 |
| Average True Range (ATR) | 0.40 | 0.31 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 70.41 | 36.07 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.